29 August 2026
For four generations, Rome’s Angelini family has built a $2.5 billion operation with drugs for depression and epilepsy in Europe. Now it’s bought its way into the U.S. market. Read the full story on Forbes: https://www.forbes.com/sites/amyfeldm...
Italy’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market. Florida-based Catalyst markets rare neuromuscular and neurological disease treatments that generated sales of $589 million last year, an increase of almost 20% over 2024.
Catalyst Pharmaceuticals (CPRX) Analysis: Zero-Debt Biotech Faces $4.1B Acquisition
3 Months Ago
